We're here to help during Covid-19. Find out more here.
Standard treatment for early breast cancer that has spread to one or two lymph nodes includes further treatment to the armpit. Research suggests that it may be possible to avoid the removal of all axillary nodes. Patients may be spared the potential side effects of having extra treatment to the axilla including lymphoedema.
The study will compare adjuvant therapy alone with adjuvant therapy plus axillary treatment (axillary node clearance (ANC) or axillary radiotherapy (ART)).
Participants will be followed up for five years.
All participants will receive adjuvant systemic therapy (chemotherapy and/or endocrine therapy). All participants may receive breast/chest wall radiotherapy. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to adjuvant therapy alone.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.